StockMacro
Menu

Halozyme Therapeutics

$91.35 +33% in 6 monthsMarket cap $10.4B

HALO on XNAS, Health Care, Halozyme Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 39% but shares fell 27% in one month while 12-month profit fell 18%.

  • BadShort interest 12% of shares, 6.8 days to cover
  • BadInsiders sold $22.1M in 90 days and bought none

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
423
Website
halozyme.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 27 Jan 2027 (an estimate: a year ago it reported on 28 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $493.0M, net income $247.0M.
Quarter to 31 Dec 2021: revenue $102.0M, net income $66.8MQuarter to 31 Dec 2021: revenue $102.0M, net income $66.8MQuarter to 31 Mar 2022: revenue $117.3M, net income $60.1MQuarter to 31 Mar 2022: revenue $117.3M, net income $60.1MQuarter to 30 Jun 2022: revenue $152.4M, net income $22.7MQuarter to 30 Jun 2022: revenue $152.4M, net income $22.7MQuarter to 30 Sep 2022: revenue $209.0M, net income $61.6MQuarter to 30 Sep 2022: revenue $209.0M, net income $61.6MQuarter to 31 Dec 2022: revenue $181.5M, net income $57.7MQuarter to 31 Dec 2022: revenue $181.5M, net income $57.7MQuarter to 31 Mar 2023: revenue $162.1M, net income $39.6MQuarter to 31 Mar 2023: revenue $162.1M, net income $39.6MQuarter to 30 Jun 2023: revenue $221.0M, net income $74.8MQuarter to 30 Jun 2023: revenue $221.0M, net income $74.8MQuarter to 30 Sep 2023: revenue $216.0M, net income $81.8MQuarter to 30 Sep 2023: revenue $216.0M, net income $81.8MQuarter to 31 Dec 2023: revenue $230.0M, net income $85.4MQuarter to 31 Dec 2023: revenue $230.0M, net income $85.4MQuarter to 31 Mar 2024: revenue $195.9M, net income $76.8MQuarter to 31 Mar 2024: revenue $195.9M, net income $76.8MQuarter to 30 Jun 2024: revenue $231.4M, net income $93.2MQuarter to 30 Jun 2024: revenue $231.4M, net income $93.2MQuarter to 30 Sep 2024: revenue $290.1M, net income $137.0MQuarter to 30 Sep 2024: revenue $290.1M, net income $137.0MQuarter to 31 Dec 2024: revenue $298.0M, net income $137.0MQuarter to 31 Dec 2024: revenue $298.0M, net income $137.0MQuarter to 31 Mar 2025: revenue $264.9M, net income $118.1MQuarter to 31 Mar 2025: revenue $264.9M, net income $118.1MQuarter to 30 Jun 2025: revenue $325.7M, net income $165.2MQuarter to 30 Jun 2025: revenue $325.7M, net income $165.2MQuarter to 30 Sep 2025: revenue $354.3M, net income $175.2MQuarter to 30 Sep 2025: revenue $354.3M, net income $175.2MQuarter to 31 Dec 2025: revenue $451.8M, net income -$141.6MQuarter to 31 Dec 2025: revenue $451.8M, net income -$141.6MQuarter to 31 Mar 2026: revenue $376.7M, net income $150.0MQuarter to 31 Mar 2026: revenue $376.7M, net income $150.0MQuarter to 30 Jun 2026: revenue $481.0M, net income $229.9MQuarter to 30 Jun 2026: revenue $481.0M, net income $229.9MQuarter to 30 Sep 2026: revenue $493.0M, net income $247.0MQuarter to 30 Sep 2026: revenue $493.0M, net income $247.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $493.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$493.0M$247.0M
30 Jun 2026$481.0M$229.9M
31 Mar 2026$376.7M$150.0M
31 Dec 2025$451.8M-$141.6M
30 Sep 2025$354.3M$175.2M
30 Jun 2025$325.7M$165.2M
31 Mar 2025$264.9M$118.1M
31 Dec 2024$298.0M$137.0M
30 Sep 2024$290.1M$137.0M
30 Jun 2024$231.4M$93.2M
31 Mar 2024$195.9M$76.8M
31 Dec 2023$230.0M$85.4M
30 Sep 2023$216.0M$81.8M
30 Jun 2023$221.0M$74.8M
31 Mar 2023$162.1M$39.6M
31 Dec 2022$181.5M$57.7M
30 Sep 2022$209.0M$61.6M
30 Jun 2022$152.4M$22.7M
31 Mar 2022$117.3M$60.1M
31 Dec 2021$102.0M$66.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.8B $1.2B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +45% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $485.4M $595.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $4.01 $4.75
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 82.3% 84.5% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 37.4% 59.3% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 26.9% 47.9% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $885.9M $602.4M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $1.1B $702.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $3.3B $1.5B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $2.2B $808.8M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 21.5 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 5.8 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 7.0 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Halozyme TherapeuticsHALO (this company) $10.4B21.55.8+45%26.9%
RepligenRGEN $10.5Bloss13.0+14%-1.5%
Kymera TherapeuticsKYMR $9.8Bloss96.3+134%-342%
Bio-TechneTECH $11.4B66.49.3+0.9%14.0%
Krystal BiotechKRYS $9.2B40.719.5+26%47.9%
VaxcytePCVX $8.8Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$22.1M

bought $0, sold $22.1M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+18%

768 13F filers vs 651

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

126.5M shares held by 13F filers (30 Sep 2026) of 114.0M outstanding (31 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

12%

13.7M shares sold short (30 Oct 2026) of 114.0M outstanding (31 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.8

13.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

0%

13.7M shares sold short in the report before, 13.7M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

46%

46% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 61%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

9

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+39%

$493.0M vs $354.3M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+0.7%

$3.0M vs $3.0M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$100K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

34

34 articles in the last 7 days; its usual week has 4.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

7.6×

34 articles in the last 7 days; its usual week has 4.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 155, 1.5× a year earlier

Price $91.35 on 20 Nov 2026, +32% over 12 months (12-month range $61.63 to $131.18)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $50.6M in the last 12 months (the 12 months before: -$28.2M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $493.0M in the latest quarter, +39% on a year earlier.
Capital spending per quarter. Capital spending $3.0M in the latest quarter, +0.7% on a year earlier.
Institutional holders (13F filers). 768 13F filers reported holding it in the latest 13F quarter, +36% on a year earlier.
Lobbying spend. Lobbying spend: $100K published in the last 12 months, -58% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 155 vs usual 78.50 (2026-09-30); 1.5x the same period a year earlier
1 Oct 2026Lobbying filingnew lobbying registration (BURRELL INTERNATIONAL GROUP LLC)
30 Sep 20268-K and other filingsDirector or officer change
18 Aug 20268-K and other filingsDirector or officer change
2 Jul 20268-K and other filingsDirector or officer change
30 Apr 20268-K and other filingsDirector or officer change
12 Mar 20268-K and other filingsDirector or officer change
12 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Dec 20258-K and other filingsDirector or officer change
8 Dec 20258-K and other filingsDirector or officer change
24 Nov 20258-K and other filingsDirector or officer change
3 Nov 20258-K and other filingsDirector or officer change
6 Oct 20258-K and other filingsDirector or officer change
6 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Mar 20258-K and other filingsDirector or officer change
25 Feb 2025Sharp changeQuarterly revenue change: quarterly revenue change, 298.0M vs usual 218.5M (2024-12-31); 1.3x the same period a year earlier
13 Feb 20258-K and other filingsDirector or officer change
13 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 78 vs usual 43 (2024-09-30); 2.1x the same period a year earlier
5 Nov 2024Sharp changeQuarterly revenue change: quarterly revenue change, 290.1M vs usual 212.5M (2024-09-30); 1.3x the same period a year earlier
20 Aug 2024Sharp changeMany funds opening a new position: many funds opening a new position, 72 vs usual 43 (2024-06-30); 1.7x the same period a year earlier
16 May 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 11.4M vs usual 514K (2023-03-31); 23.2x the same period a year earlier
23 Feb 20238-K and other filingsDirector or officer change
6 Feb 20238-K and other filingsDirector or officer change
6 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Nov 2022Sharp changeQuarterly revenue change: quarterly revenue change, 209.0M vs usual 116.6M (2022-09-30); 1.8x the same period a year earlier
18 Oct 2022Sharp changeShort interest spike: short interest spike, 12.1M vs usual 7.0M (2022-09-30); 2.0x the same period a year earlier
27 Sep 2022Sharp changeShort interest spike: short interest spike, 10.9M vs usual 6.7M (2022-09-15); 1.9x the same period a year earlier
13 Sep 2022Sharp changeShort interest spike: short interest spike, 10.7M vs usual 6.5M (2022-08-31); 1.8x the same period a year earlier
16 Aug 2022Sharp changeMany funds opening a new position: many funds opening a new position, 70 vs usual 32 (2022-06-30); 2.7x the same period a year earlier
16 Aug 2022Sharp changeShort interest spike: short interest spike, 9.1M vs usual 6.4M (2022-07-29); 1.6x the same period a year earlier
2 Aug 2022Sharp changeShort interest spike: short interest spike, 8.9M vs usual 6.4M (2022-07-15); 1.4x the same period a year earlier
24 May 20228-K and other filingsCompleted an acquisition or asset sale
15 Mar 20228-K and other filingsDirector or officer change
3 Feb 20228-K and other filingsDirector or officer change
13 Dec 20218-K and other filingsDirector or officer change
13 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Nov 2022: -$2.4M published
Month from 1 Dec 2022: -$4.0M published
Month from 1 Jan 2023: -$2.0M published
Month from 1 Feb 2023: -$2.8M published
Month from 1 Mar 2023: -$2.8M published
Month from 1 Apr 2023: -$360K published
Month from 1 Jun 2023: -$360K published
Month from 1 Jul 2023: -$1.7M published
Month from 1 Aug 2023: -$2.6M published
Month from 1 Sep 2023: -$1.7M published
Month from 1 Oct 2023: -$365K published
Month from 1 Nov 2023: -$789K published
Month from 1 Dec 2023: -$800K published
Month from 1 Jan 2024: -$720K published
Month from 1 Feb 2024: -$795K published
Month from 1 Mar 2024: -$839K published
Month from 1 Apr 2024: -$768K published
Month from 1 May 2024: -$905K published
Month from 1 Jun 2024: -$3.1M published
Month from 1 Jul 2024: -$1.4M published
Month from 1 Aug 2024: -$4.6M published
Month from 1 Sep 2024: -$4.7M published
Month from 1 Oct 2024: -$2.1M published
Month from 1 Jan 2025: -$500K published
Month from 1 Feb 2025: -$1.5M published
Month from 1 Mar 2025: -$293K published
Month from 1 Apr 2025: -$304K published
Month from 1 Jun 2025: -$3.2M published
Month from 1 Jul 2025: -$3.4M published
Month from 1 Aug 2025: -$3.8M published
Month from 1 Sep 2025: -$6.4M published
Month from 1 Oct 2025: -$4.5M published
Month from 1 Nov 2025: -$4.3M published
Month from 1 Dec 2025: -$1.5M published
Month from 1 Jan 2026: -$140K published
Month from 1 Feb 2026: -$3.9M published
Month from 1 Mar 2026: -$5.4M published
Month from 1 Apr 2026: -$3.2M published
Month from 1 May 2026: -$3.5M published
Month from 1 Jun 2026: -$3.5M published
Month from 1 Jul 2026: -$826K published
Month from 1 Aug 2026: -$6.4M published
Month from 1 Sep 2026: -$8.5M published
Month from 1 Oct 2026: -$7.2M published
Month from 1 Nov 2026: -$6.5M published
H-1B/E-3 applications certified
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $102.0M, -16% on a year earlier; public on 23 Feb 2022
Quarter ended 31 Mar 2022: $117.3M, +32% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $152.4M, +12% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $209.0M, +80% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $181.5M, +78% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $162.1M, +38% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $221.0M, +45% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $216.0M, +3.4% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $230.0M, +27% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $195.9M, +21% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $231.4M, +4.7% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $290.1M, +34% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $298.0M, +30% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $264.9M, +35% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $325.7M, +41% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $354.3M, +22% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $451.8M, +52% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $376.7M, +42% on a year earlier; public on 12 May 2026
Quarter ended 30 Jun 2026: $481.0M, +48% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $493.0M, +39% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $158K; public on 23 Feb 2022
Quarter ended 31 Mar 2022: $490K, +81% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $968K, +82% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $1.0M, +103% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $2.3M, +1384% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $11.4M, +2222% on a year earlier; public on 10 May 2023
Quarter ended 30 Sep 2023: $2.9M, +192% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $2.6M, +11% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $3.5M, -69% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $2.6M; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $1.5M, -48% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $3.1M, +18% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $950K, -73% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $1.6M, -39% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $3.0M, +100% on a year earlier; public on 4 Nov 2025
Quarter ended 31 Dec 2025: $1.4M, -53% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $3.7M, +294% on a year earlier; public on 12 May 2026
Quarter ended 30 Jun 2026: $4.2M, +167% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $3.0M, +0.7% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 290; public on 14 Feb 2022
31 Mar 2022 report: 294; public on 16 May 2022
30 Jun 2022 report: 338; public on 15 Aug 2022
30 Sep 2022 report: 326; public on 14 Nov 2022
31 Dec 2022 report: 387; public on 14 Feb 2023
31 Mar 2023 report: 355; public on 15 May 2023
30 Jun 2023 report: 344; public on 14 Aug 2023
30 Sep 2023 report: 358; public on 14 Nov 2023
31 Dec 2023 report: 381; public on 14 Feb 2024
31 Mar 2024 report: 393; public on 15 May 2024
30 Jun 2024 report: 436; public on 14 Aug 2024
30 Sep 2024 report: 474; public on 14 Nov 2024
31 Dec 2024 report: 486; public on 14 Feb 2025
31 Mar 2025 report: 519; public on 15 May 2025
30 Jun 2025 report: 517; public on 14 Aug 2025
30 Sep 2025 report: 566; public on 14 Nov 2025
31 Dec 2025 report: 587; public on 17 Feb 2026
31 Mar 2026 report: 615; public on 15 May 2026
30 Jun 2026 report: 651; public on 14 Aug 2026
30 Sep 2026 report: 768; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jul 2023: $20K published
Quarter from 1 Oct 2023: $60K published
Quarter from 1 Jan 2024: $60K published
Quarter from 1 Apr 2024: $60K published
Quarter from 1 Jul 2024: $60K published
Quarter from 1 Oct 2024: $60K published
Quarter from 1 Jan 2025: $60K published
Quarter from 1 Apr 2025: $60K published
Quarter from 1 Jul 2025: $60K published
Quarter from 1 Oct 2025: $60K published
Quarter from 1 Oct 2026: $100K published

What is unusual now

  • Made public in the last 90 days: it saw 155 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year.
  • Many funds opening a new position: saw 155 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year Public on 16 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $50.6M in the last 12 months (the 12 months before: -$28.2M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 6 sales, $22.1M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Matthew L. PosardDirectorSellplanned in advance (10b5-1)5,000$96.43$482KForm 4
16 Nov 2026Helen TorleyPRESIDENT AND CEOSellplanned in advance (10b5-1); after exercising options60,000$100.01$6.0MForm 4
8 Oct 2026Helen TorleyPRESIDENT AND CEOSellplanned in advance (10b5-1); after exercising options60,000$110.18$6.6MForm 4
2 Oct 2026Matthew L. PosardDirectorSellplanned in advance (10b5-1)5,230$108.54$568KForm 4
17 Sep 2026Matthew L. PosardDirectorSellplanned in advance (10b5-1)18,996$107.74$2.0MForm 4
11 Sep 2026Helen TorleyPRESIDENT AND CEOSellplanned in advance (10b5-1); after exercising options60,000$107.28$6.4MForm 4
19 Aug 2026Helen TorleyPRESIDENT AND CEOSellplanned in advance (10b5-1); after exercising options60,000$104.59$6.3MForm 4
11 Aug 2026Bernadette ConnaughtonDirectorSellplanned in advance (10b5-1)1,626$102.80$167KForm 4

768 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 154 opened a position, 51 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.13.7M12.0%$1.5B+397K+3.0%
Absolute Investment Advisers, LLC5.2M4.60%$10.3MNew+5.2M
Vanguard Capital Management LLC5.1M4.48%$563.8M-245K-4.6%
State Street Corp5.1M4.44%$559.0M-116K-2.2%
Vanguard Portfolio Management LLC5.0M4.37%$550.6M-312K-5.9%
Invesco Ltd.3.5M3.10%$390.2M+356K+11%
Two Sigma Investments, LP3.5M3.09%$388.5M+1.9M+113%
D. E. Shaw & Co., Inc.3.4M2.96%$372.4M+1.4M+68%
Morgan Stanley2.9M2.50%$314.7M+18K+0.6%
Boston Partners2.8M2.42%$305.1M-9,731-0.4%

Company events

All 51 company events

In 12 months: 8 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
30 Sep 2026Director or officer change8-K
22 Sep 2026Signed a major agreementSame filing: took on new debt, sold shares privately8-K
18 Aug 2026Director or officer change8-K
2 Jul 2026Director or officer change8-K
30 Apr 2026Director or officer change8-K
12 Mar 2026Director or officer change8-K
9 Dec 2025Director or officer change8-K
8 Dec 2025Director or officer change8-K

9 open postings; careers site tracked since 21 Nov 2026. Most in Legal, policy & compliance 22%, Customer success & support 11%, Finance & accounting 11%, Marketing & communications 11%.

PostedJobLocation
21 Nov 2026or earlierSenior Manager, Revenue & Gross-to-NetNot stated
21 Nov 2026or earlierExecutive Director, Pharmaceutical Manufacturing & Supply Transactions CounselLegal, policy & complianceSan Diego
21 Nov 2026or earlierSenior Netsuite Specialist 2, Information Technology Technical Support & MaintenanceCustomer success & supportNot stated
21 Nov 2026or earlierSenior Manager, Cost AccountingFinance & accountingSan Diego
21 Nov 2026or earlierDirector, HCP Marketing & Digital StrategyMarketing & communicationsNew Jersey - Ewing (100 Princeton South, Suite 300 )
5 Nov 2026Principal Scientist, Biotherapeutic FormulationsResearch & scienceSan Diego
5 Nov 2026Senior Principal Engineer, Spray Drying Process DevelopmentProcess engineering (semiconductor / materials)San Diego
3 Nov 2026Director, Regulatory AffairsLegal, policy & complianceSan Diego

Reported lobbying spend: $100K in Q3 2026, $60K in Q3 2025. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
15 Aug 2026NewBurrell International Group LLCfor Antares Pharma, Inc.Testosterone replacement therapy; FY28 Defense Authorization and Appropriations.Budget, DefenseFiling
23 Sep 2019NewForbes-Tatefor Halozyme Therapeutics, Inc.Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/accessHealth issues, Medicare/Medicaid, Science/technologyFiling
1 Feb 2016EndedJeffrey J. Kimbell & Associates, Inc.for Antares PharmaIssues related to FDA and Medical DevicesHealth issuesFiling
1 Apr 2015NewJeffrey J. Kimbell & Associates, Inc.for Antares PharmaGENERAL HEALTH CARE ISSUES, ISSUES RELATED TO FDA, MEDICAL DEVICESHealth issuesFiling
31 Dec 2007EndedFoley & Lardner LLPfor Halozyme Therapeutics IncNot statedFiling
14 Aug 2007NewFoley & Lardner LLPfor Halozyme Therapeutics IncHealth issues, PharmacyFiling

The 5 newest of 258 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

19 Nov 2024confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Halozyme Therapeutics (HALO): reported revenue of $290.1M for the quarter ended 30 Sep 2024, 1.3× the same quarter last year, while it saw 78 13F filers open a new position in the quarter ended 30 Sep 2024, 2.1× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Financials: Quarterly revenue change, became public on 5 Nov 2024
  • Institutional holdings: Many funds opening a new position, became public on 14 Nov 2024
2022-09-30: $209.0M2022-12-31: $181.5M2023-03-31: $162.1M2023-06-30: $221.0M2023-09-30: $216.0M2023-12-31: $230.0M2024-03-31: $195.9M2024-06-30: $231.4M2024-09-30: $290.1M
The quarter ended 30 Sep 2024 against the 8 quarters before it. this quarterearliernormal: $212.5M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 5 Nov 2024

Halozyme Therapeutics reported revenue of $290.1M for the quarter ended 30 Sep 2024, 1.3× the same quarter last year.

This period
$290.1M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$212.5M
Typical spread (median absolute deviation)
$17.1M
How far from its usual level
+3.1
Same quarter last year
$216.0M
History used
5,206 days
2022-09-30: $209.0M2022-12-31: $181.5M2023-03-31: $162.1M2023-06-30: $221.0M2023-09-30: $216.0M2023-12-31: $230.0M2024-03-31: $195.9M2024-06-30: $231.4M2024-09-30: $290.1M
the quarter ended 30 Sep 20248 earlier quartersnormal: $212.5M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 14 Nov 2024

Halozyme Therapeutics saw 78 13F filers open a new position in the quarter ended 30 Sep 2024, 2.1× the same quarter last year.

This period
78 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
43
Typical spread (median absolute deviation)
4
How far from its usual level
+5.9
Same quarter last year
37
History used
4,018 days
2022-09-30: 432022-12-31: 702023-03-31: 392023-06-30: 422023-09-30: 372023-12-31: 472024-03-31: 432024-06-30: 722024-09-30: 78
the quarter ended 30 Sep 20248 earlier quartersnormal: 43

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

16 Aug 2022confirmed

Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume

Halozyme Therapeutics (HALO): saw 70 13F filers open a new position in the quarter ended 30 Jun 2022, 2.7× the same quarter last year; it also had 10.7M shares sold short in the 31 Aug 2022 report, 1.8× the same report last year; and it reported revenue of $209.0M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year. Three unrelated kinds of activity within 105 days.

  • Short interest and volume: Short interest spike, became public on 27 Jul 2022
  • Institutional holdings: Many funds opening a new position, became public on 15 Aug 2022
  • Short interest and volume: Short interest spike, became public on 10 Aug 2022
  • Short interest and volume: Short interest spike, became public on 13 Sep 2022
  • Short interest and volume: Short interest spike, became public on 27 Sep 2022
  • Short interest and volume: Short interest spike, became public on 13 Oct 2022
  • Financials: Quarterly revenue change, became public on 15 Nov 2022
2020-06-30: 622020-09-30: 282020-12-31: 832021-03-31: 412021-06-30: 262021-09-30: 352021-12-31: 252022-03-31: 292022-06-30: 70
The quarter ended 30 Jun 2022 against the 8 quarters before it. this quarterearliernormal: 32
See the evidence (7 changes)

Short interest and volume: Short interest spike became public on 27 Jul 2022

Halozyme Therapeutics had 8.9M shares sold short in the 15 Jul 2022 report, 1.4× the same report last year.

This period
8.9M (the 15 Jul 2022 report)
Normal report (median of 24 earlier)
6.4M
Typical spread (median absolute deviation)
417K
How far from its usual level
+3.9
Same report last year
6.4M
History used
1,659 days
2021-06-30: 6.5M2021-07-15: 6.4M2021-07-30: 5.7M2021-08-13: 5.7M2021-08-31: 6.0M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M
the 15 Jul 2022 report24 earlier reportsnormal: 6.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 Aug 2022

Halozyme Therapeutics saw 70 13F filers open a new position in the quarter ended 30 Jun 2022, 2.7× the same quarter last year.

This period
70 (the quarter ended 30 Jun 2022)
Normal quarter (median of 8 earlier)
32
Typical spread (median absolute deviation)
6.5
How far from its usual level
+3.9
Same quarter last year
26
History used
3,195 days
2020-06-30: 622020-09-30: 282020-12-31: 832021-03-31: 412021-06-30: 262021-09-30: 352021-12-31: 252022-03-31: 292022-06-30: 70
the quarter ended 30 Jun 20228 earlier quartersnormal: 32

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 10 Aug 2022

Halozyme Therapeutics had 9.1M shares sold short in the 29 Jul 2022 report, 1.6× the same report last year.

This period
9.1M (the 29 Jul 2022 report)
Normal report (median of 24 earlier)
6.4M
Typical spread (median absolute deviation)
456K
How far from its usual level
+4.0
Same report last year
5.7M
History used
1,673 days
2021-07-15: 6.4M2021-07-30: 5.7M2021-08-13: 5.7M2021-08-31: 6.0M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M2022-07-29: 9.1M
the 29 Jul 2022 report24 earlier reportsnormal: 6.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Sep 2022

Halozyme Therapeutics had 10.7M shares sold short in the 31 Aug 2022 report, 1.8× the same report last year.

This period
10.7M (the 31 Aug 2022 report)
Normal report (median of 24 earlier)
6.5M
Typical spread (median absolute deviation)
591K
How far from its usual level
+4.8
Same report last year
6.0M
History used
1,706 days
2021-08-13: 5.7M2021-08-31: 6.0M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M2022-07-29: 9.1M2022-08-15: 9.0M2022-08-31: 10.7M
the 31 Aug 2022 report24 earlier reportsnormal: 6.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Sep 2022

Halozyme Therapeutics had 10.9M shares sold short in the 15 Sep 2022 report, 1.9× the same report last year.

This period
10.9M (the 15 Sep 2022 report)
Normal report (median of 24 earlier)
6.7M
Typical spread (median absolute deviation)
697K
How far from its usual level
+4.0
Same report last year
5.7M
History used
1,721 days
2021-08-31: 6.0M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M2022-07-29: 9.1M2022-08-15: 9.0M2022-08-31: 10.7M2022-09-15: 10.9M
the 15 Sep 2022 report24 earlier reportsnormal: 6.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Oct 2022

Halozyme Therapeutics had 12.1M shares sold short in the 30 Sep 2022 report, 2.0× the same report last year.

This period
12.1M (the 30 Sep 2022 report)
Normal report (median of 24 earlier)
7.0M
Typical spread (median absolute deviation)
959K
How far from its usual level
+3.6
Same report last year
6.2M
History used
1,736 days
2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M2022-07-29: 9.1M2022-08-15: 9.0M2022-08-31: 10.7M2022-09-15: 10.9M2022-09-30: 12.1M
the 30 Sep 2022 report24 earlier reportsnormal: 7.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 15 Nov 2022

Halozyme Therapeutics reported revenue of $209.0M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year.

This period
$209.0M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$116.6M
Typical spread (median absolute deviation)
$17.2M
How far from its usual level
+3.6
Same quarter last year
$115.8M
History used
4,475 days
2020-09-30: $65.3M2020-12-31: $121.7M2021-03-31: $89.0M2021-06-30: $136.5M2021-09-30: $115.8M2021-12-31: $102.0M2022-03-31: $117.3M2022-06-30: $152.4M2022-09-30: $209.0M
the quarter ended 30 Sep 20228 earlier quartersnormal: $116.6M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

2 Mar 2021confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Halozyme Therapeutics (HALO): saw 83 13F filers open a new position in the quarter ended 31 Dec 2020, 1.9× the same quarter last year, while it reported revenue of $121.7M for the quarter ended 31 Dec 2020, 2.3× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Institutional holdings: Many funds opening a new position, became public on 16 Feb 2021
  • Financials: Quarterly revenue change, became public on 2 Mar 2021
2018-12-31: 212019-03-31: 212019-06-30: 212019-09-30: 262019-12-31: 432020-03-31: 312020-06-30: 622020-09-30: 282020-12-31: 83
The quarter ended 31 Dec 2020 against the 8 quarters before it. this quarterearliernormal: 27
See the evidence (2 changes)

Institutional holdings: Many funds opening a new position became public on 16 Feb 2021

Halozyme Therapeutics saw 83 13F filers open a new position in the quarter ended 31 Dec 2020, 1.9× the same quarter last year.

This period
83 (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
27
Typical spread (median absolute deviation)
6
How far from its usual level
+6.3
Same quarter last year
43
History used
2,649 days
2018-12-31: 212019-03-31: 212019-06-30: 212019-09-30: 262019-12-31: 432020-03-31: 312020-06-30: 622020-09-30: 282020-12-31: 83
the quarter ended 31 Dec 20208 earlier quartersnormal: 27

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Financials: Quarterly revenue change became public on 2 Mar 2021

Halozyme Therapeutics reported revenue of $121.7M for the quarter ended 31 Dec 2020, 2.3× the same quarter last year.

This period
$121.7M (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
$54.4M
Typical spread (median absolute deviation)
$7.0M
How far from its usual level
+6.5
Same quarter last year
$53.7M
History used
3,837 days
2018-12-31: $60.2M2019-03-31: $56.9M2019-06-30: $39.1M2019-09-30: $46.2M2019-12-31: $53.7M2020-03-31: $25.4M2020-06-30: $55.2M2020-09-30: $65.3M2020-12-31: $121.7M
the quarter ended 31 Dec 20208 earlier quartersnormal: $54.4M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 16 Nov 2026Institutional holdings change

    saw 155 13F filers open a new position in the quarter ended 30 Sep 2026, 1.5× the same quarter last year.

    Same quarter last year: 105; its normal quarter is 78.5.

    See the evidence
    This period
    155 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    78.5
    Typical spread (median absolute deviation)
    7
    How far from its usual level
    +7.4
    Same quarter last year
    105
    History used
    4,748 days
    2024-09-30: 782024-12-31: 632025-03-31: 812025-06-30: 762025-09-30: 1052025-12-31: 672026-03-31: 792026-06-30: 952026-09-30: 155
    the quarter ended 30 Sep 20268 earlier quartersnormal: 78.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  2. 1 Oct 2026Lobbying record

    ANTARES PHARMA, INC.: new lobbying registration (BURRELL INTERNATIONAL GROUP LLC) (dated 15 Aug 2026)

  3. 30 Sep 2026Filings record

    Director or officer change

  4. 18 Aug 2026Filings record

    Director or officer change

  5. 2 Jul 2026Filings record

    Director or officer change

  6. 30 Apr 2026Filings record

    Director or officer change

  7. 12 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 12 Mar 2026Filings record

    Director or officer change

  9. 9 Dec 2025Filings record

    Director or officer change

  10. 8 Dec 2025Filings record

    Director or officer change

  11. 24 Nov 2025Filings record

    Director or officer change

  12. 3 Nov 2025Filings record

    Director or officer change

  13. 6 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 6 Oct 2025Filings record

    Director or officer change

  15. 21 Mar 2025Filings record

    Director or officer change

  16. 25 Feb 2025Financials change

    reported revenue of $298.0M for the quarter ended 31 Dec 2024, 1.3× the same quarter last year.

    Same quarter last year: $230.0M; its normal quarter is $218.5M.

    See the evidence
    This period
    $298.0M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $218.5M
    Typical spread (median absolute deviation)
    $17.7M
    How far from its usual level
    +3.0
    Same quarter last year
    $230.0M
    History used
    5,298 days
    2022-12-31: $181.5M2023-03-31: $162.1M2023-06-30: $221.0M2023-09-30: $216.0M2023-12-31: $230.0M2024-03-31: $195.9M2024-06-30: $231.4M2024-09-30: $290.1M2024-12-31: $298.0M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $218.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  17. 13 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 13 Feb 2025Filings record

    Director or officer change

  19. 19 Nov 2024several at once

    reported revenue of $290.1M for the quarter ended 30 Sep 2024, 1.3× the same quarter last year, while it saw 78 13F filers open a new position in the quarter ended 30 Sep 2024, 2.1× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 5 Nov 2024

    Halozyme Therapeutics reported revenue of $290.1M for the quarter ended 30 Sep 2024, 1.3× the same quarter last year.

    This period
    $290.1M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $212.5M
    Typical spread (median absolute deviation)
    $17.1M
    How far from its usual level
    +3.1
    Same quarter last year
    $216.0M
    History used
    5,206 days
    2022-09-30: $209.0M2022-12-31: $181.5M2023-03-31: $162.1M2023-06-30: $221.0M2023-09-30: $216.0M2023-12-31: $230.0M2024-03-31: $195.9M2024-06-30: $231.4M2024-09-30: $290.1M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $212.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 14 Nov 2024

    Halozyme Therapeutics saw 78 13F filers open a new position in the quarter ended 30 Sep 2024, 2.1× the same quarter last year.

    This period
    78 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    43
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +5.9
    Same quarter last year
    37
    History used
    4,018 days
    2022-09-30: 432022-12-31: 702023-03-31: 392023-06-30: 422023-09-30: 372023-12-31: 472024-03-31: 432024-06-30: 722024-09-30: 78
    the quarter ended 30 Sep 20248 earlier quartersnormal: 43

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  20. 14 Nov 2024Institutional holdings change

    saw 78 13F filers open a new position in the quarter ended 30 Sep 2024, 2.1× the same quarter last year.

    Same quarter last year: 37; its normal quarter is 43.

    See the evidence
    This period
    78 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    43
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +5.9
    Same quarter last year
    37
    History used
    4,018 days
    2022-09-30: 432022-12-31: 702023-03-31: 392023-06-30: 422023-09-30: 372023-12-31: 472024-03-31: 432024-06-30: 722024-09-30: 78
    the quarter ended 30 Sep 20248 earlier quartersnormal: 43

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  21. 5 Nov 2024Financials change

    reported revenue of $290.1M for the quarter ended 30 Sep 2024, 1.3× the same quarter last year.

    Same quarter last year: $216.0M; its normal quarter is $212.5M.

    See the evidence
    This period
    $290.1M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $212.5M
    Typical spread (median absolute deviation)
    $17.1M
    How far from its usual level
    +3.1
    Same quarter last year
    $216.0M
    History used
    5,206 days
    2022-09-30: $209.0M2022-12-31: $181.5M2023-03-31: $162.1M2023-06-30: $221.0M2023-09-30: $216.0M2023-12-31: $230.0M2024-03-31: $195.9M2024-06-30: $231.4M2024-09-30: $290.1M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $212.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  22. 14 Aug 2024Institutional holdings change

    saw 72 13F filers open a new position in the quarter ended 30 Jun 2024, 1.7× the same quarter last year.

    Same quarter last year: 42; its normal quarter is 43.

    See the evidence
    This period
    72 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    43
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +4.9
    Same quarter last year
    42
    History used
    3,926 days
    2022-06-30: 702022-09-30: 432022-12-31: 702023-03-31: 392023-06-30: 422023-09-30: 372023-12-31: 472024-03-31: 432024-06-30: 72
    the quarter ended 30 Jun 20248 earlier quartersnormal: 43

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  23. 16 May 2023Financials change

    spent $11.4M on capital projects in the quarter ended 31 Mar 2023, 23× the same quarter last year.

    Same quarter last year: $490K; its normal quarter is $514K.

    See the evidence
    This period
    $11.4M (the quarter ended 31 Mar 2023)
    Normal quarter (median of 8 earlier)
    $514K
    Typical spread (median absolute deviation)
    $300K
    How far from its usual level
    +10.9
    Same quarter last year
    $490K
    History used
    4,565 days
    2021-03-31: $270K2021-06-30: $533K2021-09-30: $496K2021-12-31: $158K2022-03-31: $490K2022-06-30: $968K2022-09-30: $1.0M2022-12-31: $2.3M2023-03-31: $11.4M
    the quarter ended 31 Mar 20238 earlier quartersnormal: $514K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  24. 23 Feb 2023Filings record

    Director or officer change

  25. 6 Feb 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 6 Feb 2023Filings record

    Director or officer change

  27. 15 Nov 2022Financials change

    reported revenue of $209.0M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year.

    Same quarter last year: $115.8M; its normal quarter is $116.6M.

    See the evidence
    This period
    $209.0M (the quarter ended 30 Sep 2022)
    Normal quarter (median of 8 earlier)
    $116.6M
    Typical spread (median absolute deviation)
    $17.2M
    How far from its usual level
    +3.6
    Same quarter last year
    $115.8M
    History used
    4,475 days
    2020-09-30: $65.3M2020-12-31: $121.7M2021-03-31: $89.0M2021-06-30: $136.5M2021-09-30: $115.8M2021-12-31: $102.0M2022-03-31: $117.3M2022-06-30: $152.4M2022-09-30: $209.0M
    the quarter ended 30 Sep 20228 earlier quartersnormal: $116.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  28. 13 Oct 2022Short interest and volume change

    had 12.1M shares sold short in the 30 Sep 2022 report, 2.0× the same report last year.

    Same report last year: 6.2M; its normal report is 7.0M.

    See the evidence
    This period
    12.1M (the 30 Sep 2022 report)
    Normal report (median of 24 earlier)
    7.0M
    Typical spread (median absolute deviation)
    959K
    How far from its usual level
    +3.6
    Same report last year
    6.2M
    History used
    1,736 days
    2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M2022-07-29: 9.1M2022-08-15: 9.0M2022-08-31: 10.7M2022-09-15: 10.9M2022-09-30: 12.1M
    the 30 Sep 2022 report24 earlier reportsnormal: 7.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 27 Sep 2022Short interest and volume change

    had 10.9M shares sold short in the 15 Sep 2022 report, 1.9× the same report last year.

    Same report last year: 5.7M; its normal report is 6.7M.

    See the evidence
    This period
    10.9M (the 15 Sep 2022 report)
    Normal report (median of 24 earlier)
    6.7M
    Typical spread (median absolute deviation)
    697K
    How far from its usual level
    +4.0
    Same report last year
    5.7M
    History used
    1,721 days
    2021-08-31: 6.0M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M2022-07-29: 9.1M2022-08-15: 9.0M2022-08-31: 10.7M2022-09-15: 10.9M
    the 15 Sep 2022 report24 earlier reportsnormal: 6.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 13 Sep 2022Short interest and volume change

    had 10.7M shares sold short in the 31 Aug 2022 report, 1.8× the same report last year.

    Same report last year: 6.0M; its normal report is 6.5M.

    See the evidence
    This period
    10.7M (the 31 Aug 2022 report)
    Normal report (median of 24 earlier)
    6.5M
    Typical spread (median absolute deviation)
    591K
    How far from its usual level
    +4.8
    Same report last year
    6.0M
    History used
    1,706 days
    2021-08-13: 5.7M2021-08-31: 6.0M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M2022-07-29: 9.1M2022-08-15: 9.0M2022-08-31: 10.7M
    the 31 Aug 2022 report24 earlier reportsnormal: 6.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 16 Aug 2022several at once

    saw 70 13F filers open a new position in the quarter ended 30 Jun 2022, 2.7× the same quarter last year; it also had 10.7M shares sold short in the 31 Aug 2022 report, 1.8× the same report last year; and it reported revenue of $209.0M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year. Three unrelated kinds of activity within 105 days.

    See the evidence (7 changes)

    Short interest and volume: Short interest spike became public on 27 Jul 2022

    Halozyme Therapeutics had 8.9M shares sold short in the 15 Jul 2022 report, 1.4× the same report last year.

    This period
    8.9M (the 15 Jul 2022 report)
    Normal report (median of 24 earlier)
    6.4M
    Typical spread (median absolute deviation)
    417K
    How far from its usual level
    +3.9
    Same report last year
    6.4M
    History used
    1,659 days
    2021-06-30: 6.5M2021-07-15: 6.4M2021-07-30: 5.7M2021-08-13: 5.7M2021-08-31: 6.0M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M
    the 15 Jul 2022 report24 earlier reportsnormal: 6.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 15 Aug 2022

    Halozyme Therapeutics saw 70 13F filers open a new position in the quarter ended 30 Jun 2022, 2.7× the same quarter last year.

    This period
    70 (the quarter ended 30 Jun 2022)
    Normal quarter (median of 8 earlier)
    32
    Typical spread (median absolute deviation)
    6.5
    How far from its usual level
    +3.9
    Same quarter last year
    26
    History used
    3,195 days
    2020-06-30: 622020-09-30: 282020-12-31: 832021-03-31: 412021-06-30: 262021-09-30: 352021-12-31: 252022-03-31: 292022-06-30: 70
    the quarter ended 30 Jun 20228 earlier quartersnormal: 32

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 10 Aug 2022

    Halozyme Therapeutics had 9.1M shares sold short in the 29 Jul 2022 report, 1.6× the same report last year.

    This period
    9.1M (the 29 Jul 2022 report)
    Normal report (median of 24 earlier)
    6.4M
    Typical spread (median absolute deviation)
    456K
    How far from its usual level
    +4.0
    Same report last year
    5.7M
    History used
    1,673 days
    2021-07-15: 6.4M2021-07-30: 5.7M2021-08-13: 5.7M2021-08-31: 6.0M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M2022-07-29: 9.1M
    the 29 Jul 2022 report24 earlier reportsnormal: 6.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Sep 2022

    Halozyme Therapeutics had 10.7M shares sold short in the 31 Aug 2022 report, 1.8× the same report last year.

    This period
    10.7M (the 31 Aug 2022 report)
    Normal report (median of 24 earlier)
    6.5M
    Typical spread (median absolute deviation)
    591K
    How far from its usual level
    +4.8
    Same report last year
    6.0M
    History used
    1,706 days
    2021-08-13: 5.7M2021-08-31: 6.0M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M2022-07-29: 9.1M2022-08-15: 9.0M2022-08-31: 10.7M
    the 31 Aug 2022 report24 earlier reportsnormal: 6.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Sep 2022

    Halozyme Therapeutics had 10.9M shares sold short in the 15 Sep 2022 report, 1.9× the same report last year.

    This period
    10.9M (the 15 Sep 2022 report)
    Normal report (median of 24 earlier)
    6.7M
    Typical spread (median absolute deviation)
    697K
    How far from its usual level
    +4.0
    Same report last year
    5.7M
    History used
    1,721 days
    2021-08-31: 6.0M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M2022-07-29: 9.1M2022-08-15: 9.0M2022-08-31: 10.7M2022-09-15: 10.9M
    the 15 Sep 2022 report24 earlier reportsnormal: 6.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Oct 2022

    Halozyme Therapeutics had 12.1M shares sold short in the 30 Sep 2022 report, 2.0× the same report last year.

    This period
    12.1M (the 30 Sep 2022 report)
    Normal report (median of 24 earlier)
    7.0M
    Typical spread (median absolute deviation)
    959K
    How far from its usual level
    +3.6
    Same report last year
    6.2M
    History used
    1,736 days
    2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M2022-07-29: 9.1M2022-08-15: 9.0M2022-08-31: 10.7M2022-09-15: 10.9M2022-09-30: 12.1M
    the 30 Sep 2022 report24 earlier reportsnormal: 7.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 15 Nov 2022

    Halozyme Therapeutics reported revenue of $209.0M for the quarter ended 30 Sep 2022, 1.8× the same quarter last year.

    This period
    $209.0M (the quarter ended 30 Sep 2022)
    Normal quarter (median of 8 earlier)
    $116.6M
    Typical spread (median absolute deviation)
    $17.2M
    How far from its usual level
    +3.6
    Same quarter last year
    $115.8M
    History used
    4,475 days
    2020-09-30: $65.3M2020-12-31: $121.7M2021-03-31: $89.0M2021-06-30: $136.5M2021-09-30: $115.8M2021-12-31: $102.0M2022-03-31: $117.3M2022-06-30: $152.4M2022-09-30: $209.0M
    the quarter ended 30 Sep 20228 earlier quartersnormal: $116.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  32. 15 Aug 2022Institutional holdings change

    saw 70 13F filers open a new position in the quarter ended 30 Jun 2022, 2.7× the same quarter last year.

    Same quarter last year: 26; its normal quarter is 32.

    See the evidence
    This period
    70 (the quarter ended 30 Jun 2022)
    Normal quarter (median of 8 earlier)
    32
    Typical spread (median absolute deviation)
    6.5
    How far from its usual level
    +3.9
    Same quarter last year
    26
    History used
    3,195 days
    2020-06-30: 622020-09-30: 282020-12-31: 832021-03-31: 412021-06-30: 262021-09-30: 352021-12-31: 252022-03-31: 292022-06-30: 70
    the quarter ended 30 Jun 20228 earlier quartersnormal: 32

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  33. 10 Aug 2022Short interest and volume change

    had 9.1M shares sold short in the 29 Jul 2022 report, 1.6× the same report last year.

    Same report last year: 5.7M; its normal report is 6.4M.

    See the evidence
    This period
    9.1M (the 29 Jul 2022 report)
    Normal report (median of 24 earlier)
    6.4M
    Typical spread (median absolute deviation)
    456K
    How far from its usual level
    +4.0
    Same report last year
    5.7M
    History used
    1,673 days
    2021-07-15: 6.4M2021-07-30: 5.7M2021-08-13: 5.7M2021-08-31: 6.0M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M2022-07-29: 9.1M
    the 29 Jul 2022 report24 earlier reportsnormal: 6.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 27 Jul 2022Short interest and volume change

    had 8.9M shares sold short in the 15 Jul 2022 report, 1.4× the same report last year.

    Same report last year: 6.4M; its normal report is 6.4M.

    See the evidence
    This period
    8.9M (the 15 Jul 2022 report)
    Normal report (median of 24 earlier)
    6.4M
    Typical spread (median absolute deviation)
    417K
    How far from its usual level
    +3.9
    Same report last year
    6.4M
    History used
    1,659 days
    2021-06-30: 6.5M2021-07-15: 6.4M2021-07-30: 5.7M2021-08-13: 5.7M2021-08-31: 6.0M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.0M2021-10-29: 6.4M2021-11-15: 6.0M2021-11-30: 6.3M2021-12-15: 6.5M2022-01-14: 6.2M2022-01-31: 6.3M2022-02-15: 6.3M2022-02-28: 6.5M2022-03-15: 6.9M2022-03-31: 7.1M2022-04-14: 7.4M2022-04-29: 8.0M2022-05-13: 7.9M2022-05-31: 8.4M2022-06-15: 8.5M2022-06-30: 8.2M2022-07-15: 8.9M
    the 15 Jul 2022 report24 earlier reportsnormal: 6.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 24 May 2022Filings record

    Completed an acquisition or asset sale

  36. 15 Mar 2022Filings record

    Director or officer change

  37. 3 Feb 2022Filings record

    Director or officer change

  38. 13 Dec 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 13 Dec 2021Filings record

    Director or officer change

  40. 2 Nov 2021Filings record

    Completed an acquisition or asset sale

Showing the newest 40 of 73 entries; narrow the window or the kind of data to see older ones.

Not listed: 266 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001159036
Ticker
HALO
Domain
halozyme.com
Employer name
antares pharma, antares pharma inc a subsidiary of halozyme (2 unverified)
Hq location
CA|SAN DIEGO|92130 (1 unverified)
Lobbying client
antares pharma, halozyme therapeutics
Name
Antares Pharma, Inc, Antares Pharma IPL AG, Elektrofi Security Corp, GLOBAL YACHT SERVICES INC and 4 more
Uei
L29GR1FX5L24
Wikidata
Q5643474
  • DOL H-1B labor condition applications and PERM certifications5 data points20 Jul 2026 to 20 Jul 2026
  • Federal lobbying disclosures (LDA)6 records, 90 data points31 Dec 2005 to 30 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)170 records4 Jan 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1139 data points31 Dec 2008 to 31 Oct 2026
  • SEC Form 4 insider transactions132 records, 476 data points29 Jun 2018 to 18 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026